Submit to JPM Review for JPM Propose a Special Issue

Journal Menu

Journal Browser

Percutaneous Management of Complex Coronary Artery Disease—Updates on Clinical Outcomes, Management Strategies and Novel Techniques

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: closed (10 February 2024) | Viewed by 3851

Share This Special Issue

Special Issue Editor

Dr. Péter Tajti

E-Mail Website
Guest Editor

Gottsegen György Hungarian Institute of Cardiology, 1096 Budapest, Hungary
Interests: percutaneous coronary intervention; complex coronary artery disease; chronic total coronary occlusion

Special Issue Information

Dear Colleagues,

In this special issue—proposed by Journal of Personalized Medicine—we are recruiting frontline researchers in the field of interventional cardiology for their valuable scientific input, with the ultimate goal of improving clinical outcomes of percutaneous coronary interventions (PCI) performed in patients with complex coronary artery disease (CCAD).

Continuous evolution of interventional cardiology and PCI has become a safe and efficient treatment option for patients presenting with stable CCAD. In recent years, however, complex coronary anatomy are more frequently witnessed in everyday clinical practice, including chronic total occlusions, bifurcations, and extreme calcification performed even in high-risk patients with severe comorbidities. Albeit, they are safely and efficiently manageable percutaneously, further optimization in patient selection, risk stratification, optimizing treatment strategies and complication management remains in focus.

This current issue welcomes original clinical research papers, reviews representing novel findings in the field of interventional cardiology and complex coronary artery disease.

Dr. Péter Tajti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

complex coronary artery disease
percutaneous coronary intervention
outcomes
chronic total occlusion
techniques
complication management
bifurcations

Published Papers (3 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

11 pages, 1094 KiB

Open AccessArticle

A Novel Strategy for Emergency Treatment of Coronary Perforations by Placing a Drug-Eluting Stent before Sealing off the Leakage with a Covered Stent to Improve Long-Term Outcomes in Patients with Coronary Artery Perforations

by Mohamed Ayoub, Noé Corpataux, Péter Tajti, Michael Behnes, Tobias Schupp, Jan Forner, Ibrahim Akin, Dirk Westermann, Volker Rudolph and Kambis Mashayekhi

J. Pers. Med. 2023, 13(11), 1542; https://doi.org/10.3390/jpm13111542 - 26 Oct 2023

Viewed by 868

Abstract

We aimed to investigate the safety, feasibility, and long-term results of drug-eluting stent implantation before covered stents for treating coronary artery perforation (CAP). Between 2015 and 2020, 12,733 patients undergoing percutaneous coronary intervention (PCI) were retrospectively analyzed. The primary endpoint was 1-year target lesion revascularization (TLR), whereas secondary endpoints included the rate of major adverse cardiac and cerebrovascular events (MACCE) and all-cause death at 1 year. A total of 159 patients with CAP were identified during the study period, of whom 47.2% (n = 75) were treated with a covered stent (CS group) because of complex and/or severe CAP and 84 (52.8%) without (non-CS group). In the majority of patients, emergency drug-eluting stent placement before covered stent implantation was feasible (n = 69, 82%). There were no significant differences among patients treated with or without a covered stent in terms of primary or secondary clinical endpoints: a similar rate of TLR (18.67% vs. 21.43%, p = 0.6646), MACCE (25.33% vs. 22.62%, p = 0.6887), and 1-year mortality (12.00% vs. 11.90%, p = 0.9853) were identified comparing cases with covered stent implantation and without. In conclusion, our study implicates that the use of covered stents for sealing coronary perforation might not impact the 1-year clinical outcome if used properly. Moreover, the emergent use of drug-eluting stents before covered stent implantation in CAP is a safe and effective method to avoid target lesion revascularization in patients treated with covered stents. Full article

(This article belongs to the Special Issue Percutaneous Management of Complex Coronary Artery Disease—Updates on Clinical Outcomes, Management Strategies and Novel Techniques)

► Show Figures

Figure 1

17 pages, 2073 KiB

Open AccessArticle

Cardiac Troponin I but Not N-Terminal Pro-B-Type Natriuretic Peptide Predicts Outcomes in Cardiogenic Shock

by Tobias Schupp, Jonas Rusnak, Jan Forner, Kathrin Weidner, Marinela Ruka, Sascha Egner-Walter, Jonas Dudda, Thomas Bertsch, Maximilian Kittel, Michael Behnes and Ibrahim Akin

J. Pers. Med. 2023, 13(9), 1348; https://doi.org/10.3390/jpm13091348 - 31 Aug 2023

Cited by 3 | Viewed by 856

Abstract

This study investigates the prognostic value of cardiac troponin I (cTNI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with cardiogenic shock (CS). Data regarding the prognostic value of cardiac biomarkers in CS is scarce, furthermore, most studies were restricted to CS patients with acute myocardial infarction (AMI). Therefore, consecutive patients with CS from 2019 to 2021 were included. Blood samples were retrieved from day of disease onset (day 1) and on days 2, 3 and 4 thereafter. The prognostic value of cTNI and NT-proBNP levels was tested for 30-day all-cause mortality. Statistical analyses included univariable t-tests, Spearman’s correlations, Kaplan–Meier analyses and multivariable Cox proportional regression analyses. A total of 217 CS patients were included with an overall rate of all-cause mortality of 56% at 30 days. CTNI was able to discriminate 30-day non-survivors (area under the curve (AUC) = 0.669; p = 0.001), whereas NT-proBNP (AUC = 0.585; p = 0.152) was not. The risk of 30-day all-cause mortality was higher in patients with cTNI levels above the median (70% vs. 43%; log rank p = 0.001; HR = 2.175; 95% CI 1.510–3.132; p = 0.001), which was observed both in patients with (71% vs. 49%; log rank p = 0.012) and without AMI-related CS (69% vs. 40%; log rank p = 0.005). The prognostic impact of cTNI was confirmed after multivariable adjustment (HR = 1.915; 95% CI 1.298–2.824; p = 0.001). In conclusion, cTNI—but not NT-proBNP—levels discriminated 30-day all-cause mortality in CS patients. Full article

(This article belongs to the Special Issue Percutaneous Management of Complex Coronary Artery Disease—Updates on Clinical Outcomes, Management Strategies and Novel Techniques)

► Show Figures

Figure 1

12 pages, 1468 KiB

Open AccessArticle

Angiographic Features and Clinical Outcomes of Balloon Uncrossable Lesions during Chronic Total Occlusion Percutaneous Coronary Intervention

by Judit Karacsonyi, Spyridon Kostantinis, Bahadir Simsek, Athanasios Rempakos, Salman S. Allana, Khaldoon Alaswad, Oleg Krestyaninov, Jaikirshan Khatri, Paul Poommipanit, Farouc A. Jaffer, James Choi, Mitul Patel, Sevket Gorgulu, Michalis Koutouzis, Ioannis Tsiafoutis, Abdul M. Sheikh, Ahmed ElGuindy, Basem Elbarouni, Taral Patel, Brian Jefferson, Jason R. Wollmuth, Robert Yeh, Dimitrios Karmpaliotis, Ajay J. Kirtane, Margaret B. McEntegart, Amirali Masoumi, Rhian Davies, Bavana V. Rangan, Olga C. Mastrodemos, Darshan Doshi, Yader Sandoval, Mir B. Basir, Michael S. Megaly, Imre Ungi, Nidal Abi Rafeh, Omer Goktekin and Emmanouil S. Brilakis Show full author list Hide full author list

J. Pers. Med. 2023, 13(3), 515; https://doi.org/10.3390/jpm13030515 - 13 Mar 2023

Cited by 2 | Viewed by 1544

Abstract

Background: Balloon uncrossable lesions are defined as lesions that cannot be crossed with a balloon after successful guidewire crossing. Methods: We analyzed the association between balloon uncrossable lesions and procedural outcomes of 8671 chronic total occlusions (CTOs) percutaneous coronary interventions (PCIs) performed between 2012 and 2022 at 41 centers. Results: The prevalence of balloon uncrossable lesions was 9.2%. The mean patient age was 64.2 ± 10 years and 80% were men. Patients with balloon uncrossable lesions were older (67.3 ± 9 vs. 63.9 ± 10, p < 0.001) and more likely to have prior coronary artery bypass graft surgery (40% vs. 25%, p < 0.001) and diabetes mellitus (50% vs. 42%, p < 0.001) compared with patients who had balloon crossable lesions. In-stent restenosis (23% vs. 16%. p < 0.001), moderate/severe calcification (68% vs. 40%, p < 0.001), and moderate/severe proximal vessel tortuosity (36% vs. 25%, p < 0.001) were more common in balloon uncrossable lesions. Procedure time (132 (90, 197) vs. 109 (71, 160) min, p < 0.001) was longer and the air kerma radiation dose (2.55 (1.41, 4.23) vs. 1.97 (1.10, 3.40) min, p < 0.001) was higher in balloon uncrossable lesions, while these lesions displayed lower technical (91% vs. 99%, p < 0.001) and procedural (88% vs. 96%, p < 0.001) success rates and higher major adverse cardiac event (MACE) rates (3.14% vs. 1.49%, p < 0.001). Several techniques were required for balloon uncrossable lesions. Conclusion: In a contemporary, multicenter registry, 9.2% of the successfully crossed CTOs were initially balloon uncrossable. Balloon uncrossable lesions exhibited lower technical and procedural success rates and a higher risk of complications compared with balloon crossable lesions. Full article

(This article belongs to the Special Issue Percutaneous Management of Complex Coronary Artery Disease—Updates on Clinical Outcomes, Management Strategies and Novel Techniques)

► Show Figures

Journal Menu

Journal Browser

Percutaneous Management of Complex Coronary Artery Disease—Updates on Clinical Outcomes, Management Strategies and Novel Techniques

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (3 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI